Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
|Articles|September 26, 2013
New Mucon Series K2P Powered Iris Valve Technology
Mucon a division of Process Components Ltd has launched its new Series K2P electrically / pneumatically actuated range of Iris valves. The Mucon brand of Iris diaphragm valves has for over sixty years been associated with the control of powders, granules, capsules and pellets to the Pharmaceutical, Chemical and Food processing sectors.
Advertisement
New Mucon Series K2P Powered Iris Valve Technology
Now in its second generation, the Series K2 Powered Iris Valves have been specifically designed for automatic and remote applications, complimenting the popular hand operated versions.
Developed for applications requiring a high level of hygiene, this valve utilises our patented, moulded diaphragm technology already employed throughout the K-Valve range.
Mucon Engineers have taken great care to balance customer requirements for quick disconnect, ease of cleaning and hygienic design with the requirements for reliability and control system integration.
All body parts are manufactured from 316 stainless steel, as standard. White moulded diaphragms of Natural Rubber, EPDM and Silicone are all manufactured from FDA approved materials.
The salient features and benefits of the new MUCON K2P valve are as follows;
- Extensively used in the Pharmaceutical, Chemical and Food sectors
- FDA approved diaphragm materials
- Full product flow control
- Non-Jamming
- No mechanical parts in contact with the product
- Slim Design
- Electric and Pneumatic actuation
- ATEX approved Cat. 1D / 2D
Advertisement
Related to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Risk-Based Life Cycle Management of Master Production and Control Records to Strengthen Data Integrity and GMP Inspection Readiness Part 2: Practical Considerations for CGMP Documentation Systems
2
CPHI Milan: USP Benchmarks Reshape Procurement Incentives
3
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
4
PharmTech’s Weekly Roundup—September 25, 2026
5